Tatva Chintan Pharm News
AllNewsAnnouncementRecos
BSE LIVE
Change:
Volume:
Open:
Prv. Close:
Today:
52-Wk:
Bid:
()
Offer:
()
NSE LIVE
Change:
Volume:
Open:
Prv. Close:
Today:
52-Wk:
Bid:
()
Offer:
()
Tatva Chintan Pharma Chem Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
| AnnouncementCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Tatva Chintan Pharma Chem Closure of Trading Window
| AnnouncementIntimation of Closure of Trading Window
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tatva Chintan Pharma Chem Compliances-Reg.24(A)-Annual Secretarial Compliance
| AnnouncementSubmission of Annual Secretarial Compliance Report for the Financial Year ended 31 March 2024 (2023-24).
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Earnings Call Transcript
| AnnouncementTranscript of the earnings call held on 03 May 2024 post announcement of the financial results of the Company for the quarter and financial year ended 31 March 2024.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Monitoring Agency Report
| AnnouncementMonitoring Agency Report for Initial Public Offering ("IPO") for the quarter ended 31 March 2024.
Tatva Chintan Pharma Chem Statement Of Deviation / Variation In Utilization Of Funds Raised Through IPO
| AnnouncementStatement of Deviation / Variation in Utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 31 March 2024.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Investor Presentation
| AnnouncementInvestor Presentation for the quarter and financial year ended 31 March 2024.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Dividend Updates
| AnnouncementOutcome of Board Meeting - Board approves Dividend
Tatva Chintan Pharma Chem Corporate Action-Board approves Dividend
| AnnouncementOutcome of Board Meeting - Board approves Dividend
Tatva Chintan Pharma Chem Board Meeting Outcome for Outcome Of The Board Meeting Held On 03.05.2024
| AnnouncementOutcome Of The Board Meeting Held On 03.05.2024
Tatva Chintan Pharma Chem Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended On 31 Ma...
| AnnouncementAudited Financial Results (Standalone and Consolidated) Of The Company For the Quarter And Financial Year Ended On 31 March 2024.
Tatva Chintan Pharma Chem Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Envir...
| AnnouncementIntimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Environmental Clearance
Tatva Chintan Pharma Chem Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
| AnnouncementFormat of the Annual Disclosure to be made by an entity identified as a Large Corporate.
| Sr. No. | Particulars | Details |
| 1 | Name of Company | Tatva Chintan Pharma Chem Ltd |
| 2 | CIN NO. | L24232GJ1996PLC029894 |
| 3 | Report filed for FY | 2023-2024 |
| Details of the Current block (all figures in Rs crore): | ||
| 4 | 2 - year block period (Specify financial years)* | FY 2023-24 and FY 2024-25 |
| 5 | Incremental borrowing done in FY (T)(a) | 0.00 |
| 6 | Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) | 0.00 |
| 7 | Actual borrowing done through debt securities in FY (T)(c) | 0.00 |
| 8 | Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) | 0 |
| 8 | Quantum of (d), which has been met from (c)(e)* | 0 |
| 9 | Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* | 0 |
| Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): | |
| 2 - year Block period (Specify financial years) | FY 2022-23 and FY 2023-24 |
| Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}# | 0.00 |
| Name of the Company Secretary :- | Ishwar Nayi |
| Designation :- | Company Secretary and Compliance Officer |
| Name of the Chief Financial Officer :- | Ashok Bothra |
| Designation : - | Chief Financial Officer |
Date: 29/04/2024
Tatva Chintan Pharma Chem Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
| AnnouncementFormat of Initial Disclosure to be made by an entity identified as a Large Corporate.
| Sr. No. | Particulars | Details |
| 1 | Name of Company | Tatva Chintan Pharma Chem Ltd |
| 2 | CIN NO. | L24232GJ1996PLC029894 |
| 3 | Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) | 4.27 |
| 4 | Highest Credit Rating during the previous FY | A- |
| 4a | Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4) | CRISIL LTD. |
| 5 | Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework | BSE |
Designation: Company Secretary and Compliance Officer
EmailId: [email protected]
Designation: Chief Financial Officer
EmailId: [email protected]
Date: 29/04/2024
Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementPursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and financial year ended 31 March 2024, is scheduled on Friday, 03 May 2024 at 05:00 p.m. IST.The Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records.The above information shall be uploaded on the website of the Company at www.tatvachintan.com.Kindly take above intimation on your record and oblige.
Tatva Chintan Pharma Chem Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Friday, 03.05.2024
| AnnouncementTatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/05/2024 ,inter alia, to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2024;2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended 31 March 2024, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.Further, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its ''''designated persons'''' regarding the closure of the Trading Window for trading in the Company''s equity shares from 01 April 2024 till the expiry of 48 hours from the date the said financial results are made public.
Tatva Chintan Pharma Chem Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations An...
| AnnouncementCompliance certificate pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended 31 March 2024.
Tatva Chintan Pharma Chem Submission Of Certificate Under Regulation 40(9) & (10) Of The SEBI (Listing Obligations And Disclosure Requirements) Re...
| AnnouncementSubmission of Certificate under Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on 31 March 2024
Tatva Chintan Pharma Chem Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
| AnnouncementCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Tatva Chintan Pharma Chem Ltd., incorporated in the year 1996, is a Small Cap company (having a market cap of Rs 2851.61 Crore) operating in Chemicals sector.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tatva Chintan Pharma Chem Closure of Trading Window
| AnnouncementIntimation of Closure of Trading Window
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tatva Chintan Pharma Chem Intimation For Updation In Website
| AnnouncementIntimation for Updation in Website
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Earnings Call Transcript
| AnnouncementTranscript of the earnings call held on 20 January 2024 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2023.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Newspaper Publication
| AnnouncementNewspaper Publication of Extract of Financial Results of the Company for the Quarter and Nine Months ended 31 December 2023.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Investor Presentation
| AnnouncementInvestor Presentation for the Quarter and Nine Months Ended 31 December 2023.
Tatva Chintan Pharma Chem Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 Dec...
| AnnouncementUnaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months ended on 31 December 2023
Tatva Chintan Pharma Chem Board Meeting Outcome for Outcome Of The Board Meeting Held On 20.01.2024
| AnnouncementPursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2023.The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 20 January 2024.Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of SEBI Listing Regulations.The above information shall be made available on the website of the Company at www.tatvachintan.com.The Board meeting commenced at 12:15 P.M. and concluded at 03:15 P.M.
Tatva Chintan Pharma Chem Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementPursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and nine months ended 31 December 2023, is scheduled on Saturday, 20 January 2024 at 04:00 p.m. (IST).The Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records.The above information is also being made available on the website of the Company at https://www.tatvachintan.com/.
Tatva Chintan Pharma Chem Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Saturday, 20.01.2024
| AnnouncementTatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/01/2024 ,inter alia, to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine month ended 31 December 2023.Further, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its ''''designated persons'''' regarding the closure of the Trading Window for trading in the Company''s equity shares from 01 January 2024 till the expiry of 48 hours from the date the said financial results are made public.The above information is also being made available on the website of the Company at www.tatvachintan.com.
